ClinicalTrials.gg
Not yet recruitingNCT07806227Updated Sep 8, 2026

Broadband Near Infrared Spectroscopy to Understand the Role of Brain Cytochrome C Oxidase in Bipolar Disorder

A Phase 4 interventional study of Lurasidone (Latuda) in Bipolar Disorder Depression, sponsored by Martin Lan. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Martin Lan · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.

Planned enrollment
12th of 17
60 · median 348
Started
2026
the only one that year
Phase 4
3 of 17
1 open now
Registered
17th of 17
by date
Lead sponsor
1 of 17
Martin Lan

Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 12th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 4, and was the 17th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing lurasidone in Bipolar Disorder, or all of them as a file.
02

Study summary

People with a diagnosis of bipolar disorder who are depressed will have a light-based imaging of the brain (Near Infrared Spectroscopy) before and after they have treatment for their depression with a standard, approved medication named lurasidone. They will also answer questions about their history, and give blood samples. The goal is to understand the role of mitochondrial activity in bipolar disorder. Healthy volunteers who have never had a psychiatric disorder will have the same procedures, but they will not receive the medication.

03

Conditions studied

  • Bipolar Disorder Depression

Keywords

  • Bipolar disorder
  • Antidepressant treatment
  • Brain Imaging
  • Depression
  • Near Infrared Spectroscopy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of bipolar disorder
  • Having symptoms of depression
  • Taking less than three medications for bipolar disorder

Exclusion criteria

Exclusion Criteria:

  • Taking any medications that cannot be combined with lurasidone
  • Any medical problems that are not well treated
  • Any drug or alcohol use disorders that are moderate or severe
  • Any severe suicidal ideation, or having had a suicide attempt in the last five years
  • Any psychotic symptoms that have occurred outside of a mood episode
  • Any electroconvulsive therapy (ECT) within the last six months
  • Currently pregnant or planning to become pregnant during the time of the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Bipolar Disorder

    Participants in a major depressive episode will receive standard treatment with lurasidone for six weeks. Doses can be adjusted based on clinical need.

    Drug: Lurasidone (Latuda)

  • No intervention
    Healthy Volunteer

    Healthy Volunteers will have all research procedures, but will not receive medication treatment

Interventions

  • The medication will be used to understand how the imaging signal changes when symptoms change during treatment.

06

What researchers measure

Primary outcomes

  1. Bipolar Depression Rating Scale

    A measure of depression severity. Higher numbers indicate more symptoms.

    Time frame: 6 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Kato T. Neurobiological basis of bipolar disorder: Mitochondrial dysfunction hypothesis and beyond. Schizophr Res. 2017 Sep;187:62-66. doi: 10.1016/j.schres.2016.10.037. Epub 2016 Nov 10. PubMed 27839913 ↗
  • Picard M, McEwen BS. Psychological Stress and Mitochondria: A Systematic Review. Psychosom Med. 2018 Feb/Mar;80(2):141-153. doi: 10.1097/PSY.0000000000000545. PubMed 29389736 ↗
  • Holper L, Mann JJ. Test-retest reliability of brain mitochondrial cytochrome-c-oxidase assessed by functional near-infrared spectroscopy. J Biomed Opt. 2018 May;23(5):1-9. doi: 10.1117/1.JBO.23.5.056006. PubMed 29766685 ↗
  • Holper L, Lan MJ, Brown PJ, Sublette EM, Burke A, Mann JJ. Brain cytochrome-c-oxidase as a marker of mitochondrial function: A pilot study in major depression using NIRS. Depress Anxiety. 2019 Aug;36(8):766-779. doi: 10.1002/da.22913. Epub 2019 May 21. PubMed 31111623 ↗

Individual participant data

Plan to share: Yes — De-identified data derived from this study will be uploaded to the National Institute of Mental Health Data Archive (NDA) at the National Institutes of Health (NIH). Aggregate, de-identified data from the study will be uploaded to the website, www.clinicaltrials.org. Data may be shared with researchers outside of New York State Psychiatric Institute, but only after the data are de-identified.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2028, 20 months later.

Of 39 non-industry phase 4 interventional studies under Bipolar Disorder, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 20 months is below that.

Counting every sponsor, half of 44 studies reached it within 43 months; a quarter within 25 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 8, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jul 30, 2028
CompletionEst.
Jul 30, 2028
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07806227
Lead sponsor
Martin Lan
Responsible party
Martin Lan (Research Scientist VI, New York State Psychiatric Institute) — Sponsor-investigator
First posted
Sep 8, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jul 30, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Sep 8, 2026

Study contacts

Martin Lan
Contact
martin.lan@nyspi.columbia.edu
646 774 7610
Martin Lan, MD PhD
principal investigator · Research Foundation for Mental Hygiene, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion